CRE Case Def from NHSN
“Any Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, or Enterobacter spp. testing resistant to imipenem, meropenem, doripenem, or ertapenem by standard susceptibility testing methods (i.e., minimum inhibitory concentrations of ≥4 mcg/mL for doripenem, imipenem and meropenem or ≥2 mcg/mL for ertapenem) OR by production of a carbapenemase (i.e., KPC, NDM, VIM, IMP, OXA-48) demonstrated using January 2017 12 - 8 MDRO and CDI Module a recognized test (e.g., polymerase chain reaction, metallo-β-lactamase test, modified-Hodge test, Carba-NP). Note: For in-plan CRE surveillance, facilities must conduct surveillance for all three organisms CRE-E.coli, CRE-Enterobacter, and CRE-Klebsiella (Klebsiella oxytoca and Klebsiella pneumoniae).”